Chinese medicine formula particle chaos: breeding power rent-seeking, repeated research and development production.

First financial reporters understand that, after years of rapid development, Chinese medicine formula particle industry, although many people entered the market, but can do large-scale only in a few, fierce competition in the market, resulting in many pharmaceutical factory clerks and hospitals to form a "benefit alliance" to carry out illegal "gold sales."
Although the outbreak has increased the exposure and recognition of Chinese medicine, the problems that plague the Chinese medicine formula particle industry still exist, and the lack of uniform standards leads to repeated waste of raw materials, research and development.
more large-scale entry to do less domestic Chinese medicine formula particle market licensees again appear to expand capacity.
September 25th, the third quarter of this year just won the provincial Chinese medicine formula particle license of liu medicine shares (603368. SH) announced that it will build a research and development base for Chinese medicine formula particles in Liuzhou City, with a total annual output value of 1.8 billion yuan.
although this is a major pharmaceutical wholesale and retail enterprises, the company's pharmaceutical industry sector accounted for less than 3% of revenue, but still "carry" this larger investment project.
" epidemic, the efficacy of Chinese medicine formula particles in clinical treatment is obvious to all, so many provinces hope that through the Chinese medicine health industry to stimulate local GDP, keen on a strong enterprise layout.
" a domestic Chinese medicine listed company in charge of the Chinese medicine formula particle plate executive Li Gang (ad) told First Financial Reporter.
Li Gang in the Chinese medicine formula particle market for more than 20 years, experienced the past this industry from the beginning to the rapid development of the process.
Chinese medicine formula particles, also known as "free-frying Chinese medicine", is in line with the concoceding norms of Chinese medicine drink tablets as raw materials, extracted, concentrated, grained from the single-flavored Chinese medicine particles.
, Japan is the first country to study Chinese medicine formula particles.
china started late and began to study in the 1990s.
Jiangyin Tianjiang Pharmaceutical Co., Ltd. ("Tianjiang Pharmaceuticals") is the first company in China to carry out the production and development of Chinese medicine formula particles, and in 1992 took the lead in the production of Chinese medicine formula particles.
July 2001, the Interim Regulations on the Administration of Chinese Medicine Formula Particles were issued, which explicitly included Chinese medicine formula particles in the scope of chinese medicine tablet management.
Since then, the chinese medicine formula particles pilot production enterprise qualification control has been in a strict state, the country's only 6 enterprises (Tianjiang Pharmaceuticals, China Resources 39, Guangdong Side Pharmaceuticals, Sichuan New Green Pharmaceuticals, Beijing Kangrentang Pharmaceuticals, Nanning Peili Pharmaceuticals) to obtain national pilot qualifications.
the end of 2015, the former State Administration of Pharmaceutical Supervision drafted the Measures for the Administration of Chinese Medicine Formula Particles (Draft for Comments), which stipulates that the supervision and management authority of Chinese medicine formula particles shall be decentralized to the level of the provincial Food and Drug Administration.
, a number of provinces have issued documents in the province to carry out research and production of Chinese medicine formula particles pilot and clinical use of medical institutions.
According to the first financial reporter combed found that from the beginning of 2020, the outbreak of new crown pneumonia has been so far, Guizhou, Tianjin, Guangxi, Hubei and other provinces have approved enterprises to carry out Chinese medicine formula particle research or issued a license.
February this year, Yiyi Pharmaceuticals (600594. SH) announced that the drug regulatory department informed that the company is a pilot enterprise for the study of Chinese medicine formulation particles in Guizhou Province; SH) announcement, the pharmaceutical regulatory department agreed to the company to study the production of Chinese medicine formula particles and in Tianjin City with Chinese medicine diagnosis and treatment subjects of medical institutions clinical use;
According to the first financial reporter incomplete combing, including the State Drug Administration initially approved six Chinese medicine formula particle test production enterprises, a total of more than 60 enterprises nationwide to obtain the production qualification of Chinese medicine formula particles.
first financial reporter was informed that there are so many enterprise layout, mainly because we see the Chinese medicine formula particles behind the development of potential market prospects.
first of all, although the current Chinese medicine formula particles in the policy is still in the pilot production stage, not completely liberalized, but in fact to get a pilot license, it is equivalent to the substantive production and sales landing.
Second, in the sales link, the Chinese medicine formula particles into the management of Chinese medicine tablets, neither need to participate in the national centralized procurement, products into the hospital has not yet a rigid "tender procedure" requirements (except for the actual situation in various places), and in the payment link, some hospitals can also refer to Chinese medicine tablets into the scope of medical insurance reimbursement.
this makes Chinese medicine formula particles compared to the general drug, has more room for sale.
" Chinese medicine formula particle industry although there are so many enterprise layout, but really have large-scale product sales of enterprises only more than 20, most enterprises because there is no large-volume product sales, license plate is basically in the 'idle' state.
" Li Gang said, Chinese medicine formula grain market cake looks very attractive, but really "eat" it is not so sweet.
According to the first financial reporter understand that the current domestic in addition to the national pilot qualification of Tianjiang Pharmaceuticals, One Side Pharmaceuticals and Red Day Pharmaceuticals and other enterprises, there are really large-scale product sales of enterprises are not many, which may be mainly in the sales of health insurance payment policies and their own operating capacity constraints and other reasons.
, according to the first financial reporter understand that at present, all over the Chinese medicine formula particle enterprises pilot degree of liberalization is not consistent.
"I think it's still a question of health care access, and the degree of liberalization of health care payments vary from place to place," he said.
" a domestic Chinese medicine listed company executive told the first financial reporter.
, as early as 2018, Kun Pharmaceutical Group (600422. SH) subsidiary Kun Traditional Chinese Medicine has become a pilot enterprise of Chinese medicine formula particles in Yunnan Province, and since then has obtained 305 cases of Chinese medicine formula particle preparation, however, the company's annual performance from the Chinese medicine formula particle products "contribution" is not much.
According to people close to Kun Chinese medicine to the first financial reporter, "after the completion of the provincial record registration, but also need health insurance to achieve sales volume, the company is still in the process of obtaining medical insurance qualifications."
"If Chinese medicine formula particle enterprises want to achieve profitability, the enterprise's own business strategy is also very critical.
" in the development of Chinese medicine formula particles, from the procurement of medicinal herbs, process technology to production, quality control, sales terminals and other links, need to work together to form an 'integrated' scale advantage, in order to form a profit.
otherwise the business would be difficult to operate.
," Li Gang told First Financial.
fierce competition at all costs to go illegal "wire" for 19 years, Chinese medicine formula particles have been referred to the management of Chinese medicine tablets, products into the hospital does not need to bid, so the hospital director has a great deal of independent decision-making power.
, according to the first financial reporter understand that a number of Chinese hospital deans "down" in the Chinese medicine formula particles power rent-seeking road.
number of judgments disclosed online by Chinese refereeing documents show that so far, a number of Chinese hospital deans have been jailed for receiving "benefits" from chinese medicine formulation particles business clerks.
, 53, was the director of the former Baisa City Chinese Medicine Hospital in Guangxi Zhuang Autonomous Region before he was jailed.
the judgment states that the court heard that "on June 16, 2015, Baise City TCM Hospital and one of the companies (acolyte, judgment note, the same below) signed the Contract for the Sale of Chinese Medicine Formula Particles."
between 2015 and 2019, in order to thank The Kingdom for giving priority to the settlement of the purchase price, one of the company's business managers, Liang, sent cash to the Kingdom ten times, totalling 300,000 yuan.
" a domestic market operator of Chinese medicine formula particles told First Financial reporter, Chinese medicine formula particles are currently in the hospital clinical use is very wide, mainly into gynecology, dermatology, oncology and other departments.
in recent years, the two-vote system, centralized volume procurement and other policies frequently, so that the domestic pharmaceutical industry suffered a reshuffle, but the Chinese medicine formula particles in the Chinese medicine drink tablets policy "embrace" smoothly through.
, the State Health Insurance Administration issued the contents of the National Health Insurance Administration's proposed symposium on the centralized procurement of biological products and traditional Chinese medicine, which clearly stated that Chinese medicine formula particles will not be included in the collection, according to the announcement.
in such a "loose" environment, the hospital has become a number of manufacturers "public relations" object.
" hospital director, the vice president in charge of drugs and the pharmacy section chief is the decision of Chinese medicine formula particles can enter the hospital's three key figures, if 'done' them, the product into the hospital on the water.
" September 25, a listed Chinese medicine company left the Chinese medicine beverage tablets sector executive Liu Hua (ad) told First Financial Reporter.
"without the dean's 'nod', it is almost impossible for Chinese medicine formula particles to enter the hospital."
" Liu Hua has worked in the above-mentioned listed companies of Chinese medicine for many years, familiar with Chinese medicine drink tablets, Chinese medicine formula particle sales, Chinese hospital management and other work.
his view, the production of Chinese medicine formula particles in order to enter the hospital market, it is necessary to form a "interest alliance" with the relevant person in charge.
, according to the judgment, as a party company clerk, Liang a docking Baise City Chinese medicine hospital business.
Liang said, "Wang Wei is the director of baisse City Hospital, the company's drug purchase and sale, settlement and so on, has a great deal of decision-making power."
in order to settle the payment priority allocated to the company, so it was many times to send money to the kingdom, hoping to get his care.
" According to Liang's testimony confirmed that from June 2015 to date, a company and Baise City Hospital about 7 million yuan of drugs sold, recovered about 4.5 million yuan.
first financial reporter understand that in the process of docking business, a company and Liang, Liang and Wang Wei, formed a "interest alliance."
, in accordance with Liang's agreement with a party's company, she can get a 15% rebate of the company's return.
and Liang is credited with a rebate of 3% to 5% of the amount returned.
" company will transfer 15% of the withdrawal to the bank card, and then withdrawals out one after another to the Kingdom.
," Liang said.
addition, Wang Wei also received a bribe of 60,000 yuan from Peili Company (axual name, judgment note, the same between 20,000 yuan).
, a business manager of Peili Company, is responsible for collection of receivables at Baise TCM Hospital.
the judgment, on March 30, 2011 and April 2, 2014, Baise City TCM Hospital and Peili signed two clinical trial agreements for the formulation of Chinese medicine particles.
June 2016 to June 2018, Yao, a salesman for the company, sent cash to Wang Wei seven times, totalling 60,000 yuan, in order to thank him for his priority payment in the settlement of medicines.
"falling down" of the Chinese hospital director more than one wang, Anhui Province, Wu Dongkun, the former director of the central hospital in Wuyang County, the same. the
judgment pointed out that, after the trial found that between 2012 and 2017, Wu Dongkun accepted the request of Anhui Yatai Pharmaceutical Co., Ltd. ("Yatai Pharmaceuticals") business manager Wang, for Wang an agent of the drug into the Wuyang County Hospital sales to help, has received Five times Wang gave 140,000 yuan.
According to Wang's testimony, he worked in Atai Pharmaceuticals from 2004 to 2017, "because Chinese medicine formulation granules are not included in the provincial tender procurement platform, belong to the scope of independent procurement of hospitals, hospitals want to use who they use."
Dongkun, director of Wuyang County Central Hospital, has the power to decide who to use chinese medicine formulation granules.
" Wang said, "Chinese medicine formula particle distribution business market competition is also relatively fierce, but also in order to enable Wuyang County Hospital to continue to sell its company's Chinese medicine formula granules, a total of 140,000 yuan to the defendant Wu Dongkun, the above-mentioned items have not been returned to it or its company."
in the process of more than ten days of interviews on the Chinese medicine formula particle industry, a number of industry insiders told the first financial reporter that the current sales environment of Chinese medicine formula particles so that the president of the Chinese hospital in a huge interest in the "attraction."
An industry insider told the first financial reporter that in the future, with more people entering the market will be more intense, "we all want to enter the hospital sales, so do not hesitate to 'walk the tight wire' sales approach seems inevitable."
" unified standards difficult to waste resources In the past few decades, the size of the Chinese medicine formula particle market has been rapid growth in China.
even so, the proportion of Chinese medicine formula particles in China's traditional Chinese medicine market is less than 2%, there is still a huge room for improvement.
public information shows that the overall size of China's Chinese medicine industry has exceeded 800 billion yuan, of which the size of Chinese medicine tablets more than 200 billion yuan, the size of the national Chinese medicine formula particles is less than 20 billion yuan.
, the problem restricting the development of the industry, mainly lies in the Chinese medicine formula particle varieties have not yet unified standards.
Recently, Pan Liwen, an associate professor at Chuxiong Medical College in Yunnan Province, suggested that, at present, there are problems such as unclear attribution of Chinese medicine formula particles, incomplete quality standards for single varieties, uniform preparation process and processing standards, confusing market prices and incomplete variety specifications.
, according to the first financial reporter understand, "unified standards" in the industry has been called for many years.
strongest voices are mainly concentrated in some head enterprises.
November 8, 2019, the State Pharmacopoeia Commission issued the "Public Notice on the Pilot Uniform Standards for Chinese Medicine Formula Particle Varieties" and said that as of the end of May 2019, a total of 437 studies on 301 varieties submitted by 14 production enterprises and 1 research institution had been received.
through the organization of 12 expert review reviews, of which 160 varieties formed a pilot unified standard of proposed publicity standards.
publicity period is three months.
, however, the publicity period has long since expired and the above-mentioned uniform standards have not yet been finalized.
the above-mentioned publicity, in accordance with the unified deployment requirements of the State Drug Administration, the State Pharmacopeia Commission in 2019 organized relevant enterprises to carry out a pilot unified standard study of Chinese medicine formula particle varieties, and organized experts to carry out standard review work.
as of the end of May 2019, a total of 437 studies on 301 varieties submitted by 14 production enterprises and 1 research institution had been received," 16 of which were reviewed through the organization of 12 expert reviews.